FGFR2+ cholangiocarcinoma: pemigatinib active as second-line treatment Presented ByProf. Antoine Hollebecque, Gustave Roussy Cancer Center, France TrialPhase 2, FIGHT-202 ConferenceESMO 2019 26 November, 2019 18:21